DPP4 and graft versus host disease: Bacigalupo et al. [147] showed that the anti-CD26 monoclonal antibody begelomab induced over 60% responses among patients with steroid refractory acute GVHD, thereby suggesting that CD26+ T cells may participate in the GVHD-related tissue damage.